Associated Genetic Biomarkers
Signal transducer and activator of transcription 2 (STAT2) is a gene that encodes a member of the STAT protein family that functions as a transcription activator when translocated to the nucleus of a cell. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as cervical cancer, endometrial cancer, and intestinal cancer.
STAT2 is altered in 0.02% of all cancers with ovarian epithelial tumor having the greatest prevalence of alterations .
The most common alteration in STAT2 is STAT2-ERBB3 Fusion (0.02%) .
STAT2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains STAT2 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with STAT2 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is STAT2 Mutation .
Irinotecan and sorafenib are the most frequent therapies in trials with STAT2 as an inclusion criteria .
Significance of STAT2 in Diseases
Malignant Solid Tumor +
STAT2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains STAT2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.